A new study reveals blood tests can predict melanoma recurrence by detecting circulating tumor DNA. Research shows 80% of stage 3 melanoma patients with positive tests experience a return of cancer.

Researchers have developed a personalized blood test that may offer a faster, less invasive way to track high-grade glioma progression.